22 January 2019 - - US-based Attention Deficit Hyperactivity Disorder treatments provider Ironshore Pharmaceuticals, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., has appointed Dr. Lewis Warrington to the position of vice president / Head of Medical Affairs, the company said.

Warrington joins Ironshore with 18 years of pharmaceutical industry experience having served in various leadership positions of increased responsibility with several global companies.

Most recently, he served as the Medical Affairs Strategic Lead at Merck where he was responsible for managing the overall medical strategy for central nervous system products in the United States.

Warrington is a dual board-certified psychiatrist (adult and child and adolescent psychiatry). Dr. Warrington's extensive experience includes: vice president and Head, Respiratory Medical Unit, and vice president and Head, Psychiatry and Neurology Medical Unit at Novartis; Senior Medical director and Therapeutic Area Head, US CNS products at Sanofi-Aventis; and Medical director, US Geodon Team at Pfizer.

Warrington received his medical degree from East Carolina University School of Medicine and completed a fellowship in child and adolescent psychiatry at the University of Florida College of Medicine.

Approved by the US Food and Drug Administration in August 2018, JORNAY PM (methylphenidate) is indicated for the treatment of Attention Deficit Hyperactivity Disorder in patients six years and older.

JORNAY PM is the only stimulant medication that is taken in the evening and has demonstrated improvement in the severity of ADHD symptoms in the early morning and throughout the day. JORNAY PM is the first drug utilising the proprietary drug delivery platform, DELEXIS. It is expected to be available commercially in the first half of this year.

ADHD is among the most common childhood psychiatric conditions with behavioral symptoms fluctuating throughout the day. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors, or be overly active.

Many home-based difficulties for children and adolescents with ADHD occur during the early morning routine (i.e. before the school day begins).

JORNAY PM is a central nervous system stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder in people 6 years of age and older. JORNAY PM may help increase attention and decrease impulsiveness and hyperactivity in people 6 years of age and older with ADHD. It is not known if JORNAY PM is safe and effective in children under 6 years of age.

CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.